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With the continued transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) throughout 
the world, identification of highly suspected COVID-19 patients remains an urgent priority. In this study, we 
developed and validated COVID-19 risk scores to identify patients with COVID-19. In this study, for patient-wise 
analysis, three signatures, including the risk score using radiomic features only, the risk score using clinical 
factors only, and the risk score combining radiomic features and clinical variables, show an excellent 
performance in differentiating COVID-19 from other viral-induced pneumonias in the validation set. For lesion-
wise analysis, the risk score using three radiomic features only also achieved an excellent AUC value. In 
contrast, the performance of 130 radiologists based on the chest CT images alone without the clinical 
characteristics included was moderate as compared to the risk scores developed. The risk scores depicting the 
correlation of CT radiomics and clinical factors with COVID-19 could be used to accurately identify patients with 
COVID-19, which would have clinically translatable diagnostic and therapeutic implications from a precision 
medicine perspective. 
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INTRODUCTION 
 
The novel severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) has been identified as the cause of 
coronavirus disease 2019 (COVID-19) in Wuhan, Hubei 
Province, China in late 2019 [1]. It spread rapidly, 
resulting in a global pandemic, with over 23,342,798 
confirmed cases and 807,383 deaths globally as of 
August 2020 [2]. COVID-19 developed through person-
to-person spread of SARS-CoV-2 via respiratory droplets 
is associated with adverse outcomes, and increased  
short- and long-term morbidity and mortality [1]. The 
identification of suspected patients with COVID-19 is 
urgently needed so that we can evaluate patients at greater 
risk and/or more vulnerable to COVID-19 and facilitate 
appropriate clinical decision making for earlier quarantine 
and interventions that could minimize the severity of 
COVID-19, thus substantially improving patient outcome. 
 
Currently, the standard for the diagnosis of COVID-19 is 
the use of the reverse transcription polymerase chain 
reaction (RT-PCR) to detect SARS-CoV-2 in lower 
throat respiratory tract secretions, sputum, swabs, or 
blood samples [3]. However, the sensitivity of the RT-
PCR varies within a range of 60–71% because its 
accuracy could be compromised by the quality of the 
RT-PCR kit, the varying lowest limit of detection (LOD) 
of virus RNA copies per mL with the kits of different 
vendors, the quality and location of specimens collected 
(upper vs. lower respiratory tract), the low viral load in 
test specimens collected, and/or sampling timing 
(different phases of the disease), thus easily leading to 
false negative results [3, 4]. 
 
Recently, the European Society for Radiotherapy and 
Oncology (ESTRO) and the American Society for 
Radiation Oncology (ASTRO) jointly issued an 
ESTRO-ASTRO consensus statement to recommend 
the use of simulation-CT in clinical practice as a 
COVID-19 screening tool during the SARS-CoV-2 
pandemic [5]. The consensus statement suggests that the 
CT imaging techniques used in radiotherapy are a 
potential screening opportunity and may be an added 
value to identify asymptomatic COVID-19 patients that 
are not identified by standard screening in hospitals 
(e.g., temperature screening and questions regarding 
COVID-19-related symptoms) [5]. The consensus was 
based on the fact that studies using CT imaging have 
identified patients with COVID-19 with negative RT-
PCR results [6, 7]. In particular, thoracic CT screening 
allows early diagnosis of COVID-19, when patients are 
still in the asymptomatic phase [5–8]. 
 
Chest radiography and CT imaging have a sensitivity of 
56–98% to identify suspected patients before the 
occurrence of positive RT-PCR detection results as well 
as use to assess disease extent and follow-up [4]. The 
principal CT manifestations include ground-glass 
opacification (GGO) with or without consolidative 
abnormalities and a bilateral, peripheral, and diffuse 
distribution with or without an involvement of the lower 
lobes [4, 9]. Especially, asymptomatic patients with 
initially negative RT-PCR results also showed early CT 
changes [9]. 
 
However, the identification of CT manifestations highly 
relies on radiologists’ clinical experience due to the 
qualitative CT features used, which might pose a 
challenge to resource-limited clinics with health care 
disparities for COVID-19 diagnosis. Meanwhile, COVID-
19 shares similar manifestations with severe acute 
respiratory syndrome (SARS), Middle East respiratory 
syndrome (MERS), and other viral pneumonias in the 
images of qualitative CT, thus significantly reducing the 
specificity of qualitative CT for COVID-19 detection 
[10]. As such, chest CT may be helpful in making the 
diagnosis, but no finding can completely confirm or 
exclude the possibility of COVID-19 without including 
other clinical characteristics due to the extremely low 
specificity of 25% of the chest CT alone for diagnostic 
purposes [4]. These aspects of qualitative CT emphasize 
limitations of the current imaging model for diagnosing 
COVID-19 before the occurrence of its clinical symptoms 
and have compelled radiologists to call for new, imaging-
based methods to answer this critical clinical question. 
 
Digital biopsy techniques have evolved to use high-
throughput processes to extract quantifiable radiomic 
features from medical images and have the potential to 
facilitate disease characterization and assessment. The 
aim of this study was to develop and validate clinically 
translatable COVID-19 risk scores encompassing chest 
CT radiomics with or without clinical characteristics 
included for distinguishing COVID-19 from other viral 
pneumonia. As a reference, we also compared the 
prediction performance of the risk scores with that of 130 
well-experienced radiologists from the epicenters of 
COVID-19 outbreak and non-epicenters in China as  
well as that of other machine learning methods in this 
study. The risk scores integrating the spatial information 
derived from chest CT radiomic features and/or clinical 
characteristics could better characterize the SARS-CoV-2 
infection landscape, which still significantly overlaps 
with other virus-induced pneumonias in visual inspection 






The clinical characteristics of patient data used are shown 
in Table 1. The COVID-19 patients had significantly 
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Table 1. Clinical characteristics of the COVID-19 and non-COVID-19 (viral-induced pneumonias) patient cohorts. 
Characteristics 
COVID-19 
patients (n = 108) 
Non-COVID-19 patients (viral-
induced pneumonias) (n = 77) 
P-value 
Age, years    
>50 41 27 0.002 
≤50 67 50 0.234 
Lesion number    
1 ≤ n < 3 14 72 <0.001 
3 ≤ n < 5 12 5 0.729 
5 ≤ n < 10 64 0 <0.001 
10 ≤ n 18 0 <0.001 
Sex    
Male 44 28 0.322 
Female 64 49 0.876 
Epidemiologic contact    
Travel history to Hubei Province, Chinaξ 12 — — 
Travel history to Wenzhou city, Zhejiang 
Province, Chinaξ 
22 — — 
Unknown exposure 74 — — 
Symptoms    
Fever 89 57 0.437 
Dyspnea 51 55 0.051 
Chest tightness 17 14 0.121 
Cough 67 75 0.532 
Sputum 23 54 0.067 
Rhinorrhea 37 65 0.213 
Asymptomatic 17* 2 — 
Laboratory results    
D-dimers, mg/L 0.51 ± 0.44 0.52 ± 0.34 0.897 
C-reactive protein, mg/L 12.32 ± 18.7 7.49 ± 14.27 0.055 
White blood cells, 109/L 3.31 ± 2.13 3.58 ± 1.94 0.112 
Creatine kinase isoenzyme, µg/L 9.12 ± 5.56 13.93 ± 5.69 <0.001 
Lactate dehydrogenase, U/L 245.91 ± 75.35 167.35 ± 42.88 <0.001 
CT manifestations    
Location    
Unilateral 1 75 <0.001 
Bilateral 107 2 <0.001 
Distribution    
Central 1 3 0.233 
Peripheral 73 72 0.191 
Central + peripheral 34 2 0.013 
Main features    
Ground-glass opacity 67 43 0.278 
Consolidation 11 9 0.055 
Linear opacity 23 12 0.231 
Mixed type 7 13 0.101 
Interstitial change    
Septal thickening 37 25 0.062 
Fine reticular opacity 11 39 0.012 
Other features    
Vascular thickening 17 39 0.054 
Crazy-paving pattern 45 39 0.123 
Pleural thickening 13 2 0.053 
Pleural effusion 0 0 — 
ξTwo epicenters of the COVID-19 outbreak in China. 
*These were tested as close contacts with confirmed COVID-19 patients. 
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higher lesion numbers, CK-MB activity, LDH activity, 
and bilateral, peripheral, or mixed central and peripheral 
pulmonary distribution than the non-COVID-19 viral-
induced pneumonia patients. Most of the symptoms, 
laboratory results, and CT manifestations had no 
significant differences between COVID-19 and non-
COVID-19 patients (Table 1). Representative images of 
COVID-19 pneumonia, adenovirus pneumonia, cyto-
megalovirus pneumonia, and influenza virus pneumonia 
are shown in Figure 1. 
 
Human diagnosis of COVID-19 
 
Supplementary Figure 5 shows the geographic 
distribution of 130 radiologists from 10 provinces in 
China, including Hubei. The performance of the  
130 radiologists based on the chest CT images only 
(without providing patients’ clinical information and 
laboratory results) was moderate due to the overlap  
of CT manifestations between COVID-19 lesions and  
non-COVID-19 viral pneumonia lesions using a 
supervised human learning format (Table 2). Notably, 
the radiologists from Hubei Province, China, the 
epicenter of the COVID-19 outbreak in China, had a 
better performance than the radiologists from outside of 
Hubei Province (P < 0.05). 
 
Patient-based risk scores 
 
The patient-based risk scores using radiomic features 
only, clinical factors only, and a combination of 
radiomic features and clinical factors are shown in 
Figure 2A–2C and Equations (2)–(4), respectively. The 
utility of the risk scores achieved area under the receiver 
operating characteristic curve (AUC) values of 0.791 
(95% confidence interval [CI]: 0651–0.932), 0.813 
(95% CI: 0.682–0.944), and 0.915 (95% CI: 0.841–
0.991), respectively, in the validation set (Table 3 and 
Figure 3), suggesting a high performance of COVID-19 




Figure 1. Representative images of COVID-19 pneumonia, adenovirus pneumonia, cytomegalovirus pneumonia, and 
influenza virus pneumonia. (A) A transverse CT image from a 35-year-old man with adenovirus pneumonia showing bilateral ground-glass 
opacities in the upper lobes with a rounded morphology (arrows). (B) COVID-19: A transverse CT image from a 57-year-old man with COVID-
19 showing more limited ground-glass opacities in the bilateral upper lobes with an elliptical morphology (arrows). (C) A transverse CT image 
obtained in a 45-year-old female with cytomegalovirus pneumonia showing bilateral ground-glass and burr-like, denser, and less transparent 
distribution (arrows). (D) A transverse CT image of a 61-year-old man diagnosed with influenza virus pneumonia showing bilateral ground-
glass opacities in the upper lobes (arrows). 
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China* (n = 40) 
Radiologists from outside 
of Hubei Province, China 





n 13 42 — 
Average time for reviewing each CT 
image (sec) 
3.2 ± 2.3 3.3 ± 2.1 0.132 
Precision 0.49  0.3  0.153 
Recall 0.30  0.23  0.121 
Specificity 0.57  0.39  0.058 
F1 0.37  0.28  0.131 




n 15 34 — 
Average time for reviewing each CT 
image (sec) 
3.3 ± 2.6 3.6 ± 2.8 0.053 
Precision 0.49  0.35  0.002 
Recall 0.29  0.24  0.042 
Specificity 0.57  0.39  0.051 
F1 0.37  0.28  0.032 
Accuracy 0.41  0.30  0.021 
Attending 
radiologists 
n 12 14 — 
Average time for reviewing each CT 
image (sec) 
3.1 ± 2.4 3.2 ± 2.9 0.129 
Precision 0.47  0.34  0.215 
Recall 0.29  0.22  0.055 
Specificity 0.54  0.40  0.067 
F1 0.35  0.26  0.042 
Accuracy 0.39  0.29  0.102 
Overall 
Average time for reviewing each CT 
image (sec) 
3.2 ± 0.1 3.4 ± 0.2 0.054 
Precision 0.48  0.35  <0.001 
Recall 0.29  0.23  0.027 
Specificity 0.56  0.39  0.002 
F1 0.36  0.28  0.034 
Accuracy 0.41  0.30  0.029 
*Hubei Province was the epicenter of the COVID-19 outbreak in China. 
 
The patient based risk score using radiomic features only
3.785 19.563  GLRLM_LRLGE_(25,90)
0.002 ID_Global_Max
−
= − + 
+ 
   (2) 
 
The patient based risk score using clinical factors only









The patient based risk score combining radiomics
 and clinical features












where GLRLM_LRLGE_(25, 90) represents the 
radiomic feature, long-run, low gray-level emphasis, 
which describes the distribution of the long 
homogeneous runs with low gray-levels within the 
image. The numbers in the brackets represent the 
parameters used to calculate that particular radiomic 
feature. ID_Global_max represents the radiomic feature 
intensity direct global max, which describes that the 
binary mask was preprocessed for the features derived 
directly from the image intensity. A detailed description 
of the parameters used is shown in Figure 2. 
 
In contrast, the developed patient-based random forest 
models demonstrate comparable AUC values, precision, 
recall, specificity, F1, and accuracy as compared to the 
patient-based risk scores in the validation set (Table 3). 
The results of the decision curve analysis (DCA) to 
evaluate the clinical utility of the risk scores and the 
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Figure 2. The patient-based COVID-19 risk scores demonstrated by nomograms. (A) The risk score using radiomic features only. (B) 
The risk score using clinical factors only. (C) The risk score combining radiomic features and clinical factors. GLRLM_LRLGE_(25, 90) represents 
the radiomic feature long run low gray-level emphasis, which describes the distribution of the long homogeneous runs with low gray-levels 
within the image. The numbers in the bracket represents the parameters used to calculate that particular radiomic feature. The parameters 
of 25 and 90 in GLRLM_LRLGE represent the binary mask in 2.5D and 90 degrees, which describes that the GLRLM was computed in 2D slice 
by slice; then, the occurrence of run length from 90 degrees from all 2D image slices was summed. ID_Global_max represents the radiomic 
feature intensity direct global max, which describes that the binary mask was preprocessed for the features derived directly from the image 
intensity. The binary mask in ID_Global_max can be modified through intensity thresholding, by binary erosion, and using only the binary 
slice with the maximum area. The unit for lactate dehydrogenase is U/L. The unit for creatine kinase isoenzymes is µg/L. Supplementary 
Appendix 2 explains how to use the nomograms. 
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Table 3. The classification performance using patient-based COVID-19 risk scores and random forest models. 
Signature AUC Precision Recall Specificity F1 score Accuracy 
Delong test for 
AUC values 
Training set        
COVID-19 risk score using 













Z = 7.241,  
P = 0.000 
COVID-19 risk score using 













COVID-19 risk score using 




























Z = 8.574,  
P = 0.000 














Random forest using radiomic 













Validation set       
Z = 9.307,  
P = 0.000 
COVID-19 risk score using 













COVID-19 risk score using 













COVID-19 risk score using 




























Z = 7.896,  
P = 0.000 














Random forest using radiomic 













The values in the brackets represent the 95% confidence interval. 
Abbreviations: AUC, area under the ROC curve. 
 
random forest models built in this study are shown  
in Figure 3E, 3F. The risk scores show a comparable 
clinical utility as compared to the random forest  
models. 
 
Lesion-wise COVID-19 risk score with radiomic 
features only 
 
To characterize different infectious lesions within the 
same patient, a lesion-based risk score using three 
radiomic features alone was also constructed (Figure 4 
and Equation (5)). The utility of the risk score achieved 
an AUC value of 0.931 (95% CI: 0.898–0.956) (Table 4 
and Figure 5A). 
 
The lesion
based risk score using radiomics features alone







       (5) 
where GLRLM_Correlation_(25,0,1) represents the 
radiomic feature gray-level co-occurrence matrix with 
statistical measurement of correlation between a pixel 
and its neighbor over the whole image. The numbers in 
the brackets represent the parameters used to calculate 
that particular radiomic feature. ID_Local_Range_Std 
represents the radiomic feature of intensity direct in the 
neighborhood region, which describes the standard 
deviation among all the voxels. GOH_Percentile_(15) 
represents the radiomic feature gradient orient histogram, 
which describes the percentiles of the occurrence 
probability values in the histogram of the image. A 
detailed description of the parameters used is shown in 
Figure 4. 
 
In contrast, the lesion-based weighted support vector 
machine (WSVM) model using the radiomic features 
only demonstrates a comparable AUC value, precision, 
recall, specificity, F1, and accuracy as compared to the 
lesion-based risk score (Table 4). The results of the 
DCA analysis to evaluate the clinical utility of the risk 
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Figure 3. The receiver operating characteristic (ROC) curves and the decision curve analysis (DCA) for the patient-based risk 
scores and random forest models. (A) ROC curve for patient-based risk scores in the training set. (B) ROC curve for patient-based risk 
scores in the validation set. (C) ROC curve for patient-based random forest models in the training set. (D) ROC curve for patient-based 
random forest models in the validation set. (E) DCA for patient-based risk scores in the validation set. (F) DCA for patient-based random 
forest models in the validation set. In (E) and (F), the x-axis of the decision curve is the threshold of the predicted probability using the risk 
score to classify COVID-19 and non-COVID-19 patients. The y-axis shows the clinical decision net benefit for patients based on the 
classification result in this threshold. The decision curves of the treat-all scheme (the monotonically decreasing dash-line curve in the figure) 
and the treat-none scheme (the line when x equals zero) are used as references in the DCA. In this study, the treat-all scheme assumes that 
all the patients had COVID-19; the treat-none scheme assumes that none of the patients had COVID-19. Abbreviations: AUC, area under the 
ROC curve; 95% CI, 95% confidence interval. 
 
www.aging-us.com 9194 AGING 
score and the WSVM model using radiomic features 




During the incubation period of SARS-CoV-2, before 
the onset of clinical symptoms confirmed by positive 
nucleic acid detection, about 96% of patients would 
have non-specific CT imaging changes similar to other 
viral pneumonias in the lungs, i.e., GGO, patchy 
consolidation, and sub-solidification [4, 9, 11, 12]. In 
this study, the performance of the radiomics-based risk 
scores was compared to that of human diagnosis in 
differentiating COVID-19 from viral pneumonia. We 
demonstrated that both the patient-based risk score 
using radiomic features only and the lesion-based risk 
score using radiomic features only have significantly 
better classification abilities than the human diagnosis 
at the patient- and lesion-wise levels. This can partially 
be attributed because without the aid of other clinical 
information, radiologists might achieve a relatively low 
sensitivity and specificity in differentiating COVID-19 
from viral pneumonias based only on the chest CT 
manifestations. 
 
The risk score could provide a quantitative measure to 
appropriately adjust the cut-off value based on desired 
levels of recall and specificity to reduce the adverse 
consequences of false negatives in the differentiation  
of COVID-19. In addition, with the quantitative 
measurements used, it might be useful to longitudinally 
monitor disease progress over time or recurrence in the 
recovered COVID-19 patients using delta radiomics 
methods, although this possibility is still under 
investigation. 
 
In the patient-based COVID-19 risk scores, three 
clinical variables, i.e., lesion number, LDH activity, and 
CK-MB activity, show discriminative abilities for 
COVID-19 detection. Notably, the imaging pattern 
showing a multifocal appearance with a lesion number 
larger than 3–5 could be used as a rapid cut-off in the 
case of a strong suspicion of SARS-CoV-2 infection. 
Meanwhile, LDH serves as an inflammatory predictor 
in many pulmonary diseases, such as obstructive 
disease, microbial pulmonary disease, and interstitial 
pulmonary disease [13, 14]. A recent study showed that 
refractory COVID-19 patients had increased blood LDH 
and CRP levels. Moreover, another study demonstrated 
that COVID-19 patients treated in the ICU had higher 
levels of LDH and CRP than those not treated in the 
ICU [15]. These observations suggest that LDH levels 
might reflect the acute severe systemic inflammatory 
response involved in cell-mediated immunity and 
cytokine storms caused by SARS-CoV-2 infection, 
which is a distinguishable biochemical parameter for 
inflammation in the risk score. 
 
Furthermore, a previous study suggested that the 




Figure 4. The lesion-based risk score using three radiomic features only. GOH_Percentile_(15) represents the radiomic feature 
gradient orient histogram, which describes the percentiles of the occurrence probability values in the histogram of the image. The numbers in 
the brackets represent the parameters used to calculate that particular radiomic feature. The parameter of 15 in GOH_Percentile represents 
the histogram percentile. GLCM_Correlation_(25,0,1) represents the radiomic feature gray-level co-occurrence matrix with statistical 
measurement of correlation between a pixel and its neighbor over the whole image, which describes that the gray-level co-occurrence matrix 
was computed from the image inside the binary mask in 2.5D with the direction of the angle of intensity pair at 0 degrees and the distance 
between the intensity pairs at 1. ID-Local_Range_Std represents the intensity direct in the neighborhood region, which describes the 
standard deviation among all the voxels. 
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Table 4. The diagnosis performance using the lesion-based risk score and weighted support vector machine. 
















(0.834–0.981) Z = 4.371,  














The values in the brackets represent the 95% confidence interval (95% CI). 
Abbreviations: AUC, area under the curve. 
 
with SARS-CoV-2 mRNA levels in RT-PCR positive 
patients [16]. As such, all three clinical variables in the 
risk scores might emphasize the underlying biological 
mechanism(s) related to COVID-19. The immunological 
mechanism of SARS-CoV-2 infection still requires 
further investigation. 
 
In the patient-based COVID-19 risk scores, two radiomic 
features, GLRLM_LRLGE_(25,90) and ID_Global_max, 
were selected to build the risk score with significantly 
strong discriminative abilities for COVID-19 detection 
(i.e., the features with P < 0.001 in the multivariable 
logistic regression). GLRLM_LRLGE had a higher 
weight (larger coefficient) in the risk score compared to 
other radiomics and clinical features. GLRLM_LRLGE 
analyzes the spatial information within chest CT image 
runs in the upper right quadrant of the GLRLM with long 
run lengths and low gray-levels. The longer runs with 
different gray-level intensities are closely linked with 
coarse texture and regional heterogeneity as compared to 
fine texture [17]. Therefore, GLRLM_LRLGE might be 
associated with the coarseness of COVID-19 [18]. 
Consequently, a higher GLRLM_LRLGE, i.e., a coarser 
texture on chest CT images, may be associated with a 
higher risk of occurrence of COVID-19 [19]. 
 
Interestingly, three different radiomic features, GOH_ 
Percentile_(15), GLCM_Correlation_(25,0,1), and ID_ 
Local_Range_Std, were identified in our lesion-based 
analysis. In particular, previous studies suggested that a 
GLCM_correlation value might be inversely related with 
the levels of vascular endothelial growth factor (VEGF), 
which controls critical physiological functions in the lung 
[20–22]. For example, a decrease in VEGF expression is 
believed to be associated with acute lung injury and 
alkaloid monocrotaline-pulmonary hypertension [23], 
which is one of the most common comorbidities in 




Figure 5. The receiver operating characteristic (ROC) curves and the decision curve analysis (DCA) for the lesion-based risk 
score and weighted support vector machine model using radiomic features alone. (A) ROC curve. (B) DCA analysis. In (B), the x-
axis of the decision curve is the threshold of the predicted probability using the risk score to classify COVID-19 and non-COVID-19 patients. 
The y-axis shows the clinical decision net benefit for patients based on the classification result in this threshold. The decision curves of the 
treat-all scheme (the monotonically decreasing dash-line curve in the figure) and the treat-none scheme (the line when x equals zero) are 
used as references in the DCA. In this study, the treat-all scheme assumes that all patients had COVID-19; the treat-none scheme assumes 
that none of the patients had COVID-19. Abbreviations: AUC, area under the curve; 95% CI, 95% confidence interval. 
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radiomic features and the phenotypes linked to COVID-
19 is not well understood at present. 
 
There are different processing methods for patient-
based analysis. Some studies selected the largest lesion 
and/or the most metabolically active lesion as a 
representative lesion for that patient based on a method 
reported previously [25, 26]. However, the large 
heterogeneous lesions (often necrotic and/or with 
multiple uptake peaks) may underestimate image 
texture measurements [27]. Nevertheless, all the lesions 
could be used for radiomics analysis, which enriches the 
analysis through the use of the information derived from 
all lesions. However, the method of averaging the 
radiomic values of all lesions as the characteristic value 
for one particular radiomic feature could dilute the 
feature value of large lesions by other small lesions. As 
such, in this study, a weighted power mean method was 
used in the patient-based analysis to emphasize that the 
lesions with relatively large volume represent the main 
characteristics of the biological behavior and 
characteristics of the disease type, while still retaining 
the other small lesions representing a certain kind  
of disease progression. In contrast, the lesion-based 
analysis allowed us to examine each individual lesion 
with a consideration of different infectious lesions 
within the same patient. 
 
There could be certain bias introduced in the boundary 
and volume contoured in the manual delineating process 
by different radiologists, which could certainly affect the 
radiomics values calculated. However, this kind of inter-
observer variation mainly influences the shape-related 
radiomic features. It has relatively limited influence on 
the features of GLRLM_LRLGE_(25, 90), ID_Global_ 
Max, GOH_Percentile_(15), GLCM_Correlation_(25,0,1), 
and ID_Local_range_std selected in this study. A 
previous study conducted by eight research centers in the 
United States and one medical imaging center in Canada 
suggested that the segmentation mainly affects the global 
shape descriptors features, but has relatively little effect 
on the texture and intensity features of the entire three-
dimensional volume [28]. Also, GLRLM_LRLGE_(25, 
90), ID_Global_Max GOH_Percentile_(15), GLCM_ 
Correlation_(25,0,1), and ID_Local_range_std are  
five important features in the texture and intensity 
features category. A verification study is described in 
Supplementary Appendix 3. 
 
As a retrospective study, this study has several 
limitations. First, the patient cohort in this study is 
relatively small. The use of digital biopsy technologies 
with promising retrospective radiomics analyses  
must still be further evaluated in prospective clinical 
trials, thus facilitating a better personalized patient 
management. Second, all patients are from Zhejiang 
Province, China, and might not fully represent the 
spectrum of COVID-19 phenotypes. The relationships 
between radiomic features and their underlying immune 
interactions and biological mechanism(s) directing 
COVID-19 progression at the early stage of SARS-CoV-
2 infection also remain to be explored. Third, although 
the radiomic features and clinical variables associated 
with disease progression were not evaluated in this study, 
the findings of this research may still provide useful 
insights for future studies to identify the underlying 
mechanism(s) and relevant radiomic features for disease 





The point-of-care COVID-19 risk scores could be an 
easy-to-use tool to quantitatively differentiate COVID-19 
from other viral pneumonias. The risk scores using chest 
CT radiomic features and/or clinical characteristics could 
better characterize the SARS-CoV-2 infection landscape, 
which still significantly overlaps with other virus-induced 
pneumonias in visual inspection of CT manifestations. 
The risk scores developed could potentially afford a 
clinically translatable means to improve the diagnostic 
confidence using chest CT for COVID-19 detection in 
the future. 
 




This study was approved by the Hangzhou Xixi 
Hospital Institutional Review Board. As this is a 
retrospective study, the need for written informed 
consent from patients was waived. A total of 193 
patients confirmed with COVID-19 or other types of 
viral pneumonia were enrolled in this study. Eight 
patients with negative chest CT imaging result were 
excluded. A total of 108 patients with COVID-19 
confirmed by RT-PCR between December 2019 and 
March 2020 in the Hangzhou Xixi Hospital were 
retrospectively included into this study. Another group 
of 77 patients with influenza virus-induced, adenovirus-
induced, syncytial virus-induced, and cytomegalovirus-
induced pneumonias from Hangzhou First People’s 
Hospital (19 cases) and Hangzhou Xixi Hospital (58 
cases) were used as controls. 
 
The patients’ electronic medical data were retrieved 
from the Hospital Information System (HIS). The  
high-resolution CT images were retrieved from the 
picture archiving and communication system of  
the hospitals. The patients’ RT-PCR results were 
retrieved from the electronic medical records in the 
HIS. The patients with negative chest CT results or 
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lacking both chest CT and RT-PCR examinations were 
excluded from this study. Figure 6 summarizes the 
study workflow and methods. 
 
Baseline clinical data, including patient’s age, gender, 
lesion number, and five biochemical indicators 
recommended in the “Handbook of COVID-19 
Prevention and Treatment,’’ [29] including white blood 
cell count (WBC), C-reactive protein (CRP) levels, 
creatine kinase isoenzyme (CK-MB) activity, lactate 
dehydrogenase (LDH) activities, and plasma D-dimer 
(DD) levels, were collected by reviewing the medical 
records and data of serial CT imaging, including 
baseline, mid-treatment, and post-treatment CT scans, 
were also recorded to monitor the disease progression. 
The patients’ daily basic status, daily examination 
results, and complications were also analyzed to check 
how the disease progressed. Based on the RT-PCR 
results for COVID-19 confirmation, the enrolled 
patients were divided into two groups, i.e., the COVID-
19 group and the non-COVID-19 viral pneumonia 
group. 
 
CT image acquisition 
 
All patients included underwent chest CT imaging using 
a two multi-detector row CT system (GE Revolution 
Evo CT, Chicago, USA; Siemens SOMATOM Emotion 
16, Erlangen, Germany). The acquisition parameters 
were as follows: 120/130 kV, 100/10–240 mA, 0.35- or 
0.8-second rotation time, a layer spacing of 5 mm, an 
acquisition layer thickness of 5 mm, high-resolution 
reconstruction with a lung window layer thickness of 
1.25/1.50 mm, a detector collimation of 16×0.5 mm or 
64×0.625 mm, a field of view of 350×350 mm, and an 
image matrix of 512×512. The CT scans before onset of 
symptoms or CT scans done ≤1 week after symptom 
onset were used as baseline. The baseline CTs of highly 
suspected patients were used in this study. GGO and/or 
consolidation are the main manifestations in the CT 
images at this early stage. The other CT imaging 
patterns included linear opacity, mixed type and 
interstitial change patterns including septal thickening 
and fine reticular opacity, and other features including 
vascular thickening, crazy paving pattern, pleural 
thickening, and pleural effusion. 
 
Human diagnosis of COVID-19 using a human 
supervised learning fashion 
 
To compare the classification performance between the 
COVID-19 risk scores developed and radiologists, 147 
radiologists were invited to differentiate COVID-19 
from the virus-induced pneumonias based on the CT 
manifestations only. The diagnosis was performed using 
a human supervised learning fashion. 
A total of five COVID-19 CT images and five influenza 
virus-induced, adenovirus-induced, syncytial virus-
induced, and cytomegalovirus-induced pneumonia 
images were randomly drawn from the total patient 
cohort to form a learning sample set. These learning 
sample images along with the CT manifestations 
described in the China Clinical Consensus on 
Radiological Diagnosis on COVID-19 [29] were used to 
train 130 radiologists in China with thoracic CT 
diagnosis experiences ranging from assistant attending 
radiologists or associate attending radiologists to 
attending radiologists using a human supervised learning 
fashion. The radiologists were then given the remaining 
176 CT images without the clinical and follow-up 
information provided. Based on the CT manifestations 
they learned from the 10 image samples provided, the 
radiologists diagnosed whether these 176 CT images 
were COVID-19 or influenza virus-/adenovirus-/ 
syncytial virus-/cytomegalovirus-induced pneumonias. 
The accuracy and the average time for diagnosis per CT 
image were used for statistical analysis. To rule out the 
random diagnosis, two equal CT images were mixed 
within the 176 CT images, and if the radiologist’s 
answers were not consistent for these two images, his or 
her answers were excluded from the statistical analysis. 
A total of 130 radiologists’ diagnoses were eligible for 
statistical analysis (40 radiologists from Hubei Province, 
the epicenter of the COVIA-19 outbreak in China, and 90 
radiologists from outside of Hubei Province). 
 
Radiomic feature extraction 
 
Before extracting all chest CT radiomic features, 3D 
adaptive histogram equalization enhancement (AHEE-
3D) and edge preserve smooth 3D (EPS-3D) methods 
were used to remove random noise in the images. The 
lesions of pneumonias on CT images were reviewed and 
manually delineated by two experienced attending 
radiologists who were blind to the clinical and follow-
up information. The final contour for each lesion was 
agreed upon by both radiologists. The patient-based and 
lesion-based analyses were performed. The lesion 
region of interest (ROI) was segmented on the CT 
image as the only input for radiomics analysis of 
pneumonia. 
 
A total of 1766 radiomic features were extracted from 
each ROI delineated using the image biomarker explorer 
(IBEX) public platform developed by the University of 
Texas MD Anderson Cancer Center for feature extraction 
and classification of radiomic features [30, 31]. The 
radiomic features extracted include seven categories: 
shape, intensity direct, intensity histogram, gray-level co-
occurrence matrix (2.5D and 3D), neighbor intensity 
difference (2.5D and 3D), gray-level run length matrix 
(2.5D), and intensity histogram Gauss fit. 
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Figure 6. The workflow for the development and validation of COVID-19 risk scores. 
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It is believed that some of the radiomic features are 
sensitive to each step of the data processing procedure, 
including image acquisition settings, image 
reconstruction algorithm, and the digital image 
preprocessing procedure, so that the repeatability and 
reproducibility of the extraction of these radiomic 
features are easily compromised [32]. To account for 
the potential impact of the accuracy of radiomic feature 
extraction, the radiomic feature extraction procedure 
was repeated twice and Lin’s concordance correlation 
coefficient (CCC) tests were performed to assess the 
feature reproducibility in repeated feature extraction 
[33, 34]. Only the 1237 radiomic features showing high 
CCC values (CCC > 0.99) were used. With 1237 
radiomic features selected, 510 features with null value 
were eliminated and the remaining 727 radiomic 
features plus 9 clinical variables (lesion number, age, 
gender, WBC, LC, CRP level, LDH activity, CK-MB 
activity, and plasma DD level) were used for further 
analysis. 
 
Patient-based risk scores 
 
Of the patient data, 25% was randomly selected as an 
independent validation set (n = 46) and the remaining 
75% of the patient data were used for the training set  
(n = 139). The ratio of COVID-19 to non-COVID-19 
patients was about 1.41:1 in the training and validation 
sets (in the training set, COVID-19:non-COVID-19 = 
81:58 patients; in the validation set, COVID-19:non-
COVID-19 = 27:19 patients). 
 
For our patient-based analysis, the same features 
extracted from multiple lesions within one single patient 
were combined using a weighted power mean method 
[35]. Briefly, all lesions of the patient were delineated 
and the radiomic features were extracted. A weighting 
calculation was performed to combine the same feature 
from different lesions within the same patient as 

























                                                (6) 
 
where F(j) represents the value of the j-th radiomic 
feature of the patient, i represents the i-th lesion of the 
patient, V(i) represents the volume of the i-th lesion, n 
represents the number of lung lesions in the patient, VT 
represents the total volume of all lesions in the patient, 
and fj(i) represents the value of feature j in the i-th 
lesion. The weight assigned was based on the volume of 
the lesion. The larger the lesion volume, the greater the 
weight value of the features extracted from that lesion. 
Thus the contribution of the features extracted from this 
lesion to the patient’s radiomic feature was also greater. 
 
Owing to the imbalanced sample distribution between 
COVID-19 and non-COVID-19 patients (the number of 
non-COVID-19 patient is lower than the number of 
COVID-19 patients), synthetic minority over-sampling 
technology [36–40] was used to generate synthetic non-
COVID-19 patient samples in the training set so that a 
synthetically class-balanced training set could be 
achieved prior to training the models in this study. 
Briefly, for each minority sample “a” in the non-
COVID-19 patient group, the synthesis strategy was 
applied to randomly select a minority sample “b” from 
its nearest neighbors. And then one point was randomly 
selected as the newly synthesized non-COVID-19 
patient sample on the line between “a” and “b,” so that 
the ratio of COVID-19 and non-COVID-19 patients in 
the training set was close to 1:1. 
 
Three signatures, including a risk score using radiomic 
features only, a risk score using clinical factors only, and 
a risk score combining radiomic features and clinical 
variables, were built in this study (Figure 7). For the 
construction of the risk score using radiomic features 
only and the risk score combining radiomic features and 
clinical variables, principal component analysis (PCA), 
the Mann–Whitney U test, and least absolute shrinkage 
and selection operator (LASSO) regression with a four 
fold cross-validation method and a 100 times iterative 
selection process were successively applied to eliminate 
redundant features and irrelevant variables to establish 
the COVID-19 risk scores. A multivariate logistic 
regression method was used to build these two risk 
scores. For the construction of the risk score using 
clinical factors only, because the number of clinical 
factors is much lower than the number of radiomic 
features, a multivariate logistic regression method  
was directly applied to build the clinical signature. The 
model performance of the three risk scores was 
evaluated in the training and independent validation sets. 
 
For the construction of the risk score using radiomic 
features only and the risk score combining radiomic 
features and clinical factors, PCA was used to reduce 
the feature dimensionality and select the radiomic 
features and radiomic features plus clinical variables 
that accounted for 90% of the significant feature subset 
variability to increase the discriminative ability. After 
PCA analysis, the feature dimensionality was reduced 
from 727 radiomic features to 32 features for the risk 
score using radiomic features only (Supplementary 
Table 1), and from 727 radiomic features plus 9 clinical 
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Figure 7. The workflow of the construction of the patient-based risk scores using radiomic features only, the risk score using 
clinical factors only, and the risk score combining radiomic features and clinical variables using a multivariate logistic 
regression method and a random forest model. 
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variables to 26 features for the risk score combining 
radiomic features and clinical factors (20 radiomic 
features plus 6 clinical variables including lesion 
number, gender, WBC, CRP level, LDH activity, CK-
MB activity, and plasma DD level) (Supplementary 
Table 2). 
 
The Mann–Whitney U test was used to further explore 
the potential association of the features/variables 
selected from PCA with COVID-19 and further reduce 
the feature dimensions. For the risk score using radiomic 
features only (Supplementary Table 3), the feature 
dimensions were reduced from 32 to 20 radiomic 
features. For the risk score combining radiomic features 
and clinical factors, the feature dimensions were reduced 
from 26 to 17 features (11 radiomic features plus 6 
clinical variables including lesion number, gender, 
WBC, CRP level, LDH activity, and CK-MB activity) 
(Supplementary Table 4). 
 
To select the most suitable features for classification of 
COVID-19, LASSO regression with a four fold cross-
validation method and a 100 times iterative selection 
process was used to continually choose non-redundant 
and the most robust radiomic features and radiomic 
features and clinical variables, respectively [41, 42]. The 
coefficient of each variable was controlled by the 
parameter λ in the LASSO method and only the features 
with non-zero coefficients were selected. The 
misclassification error was calculated to minimize the 
binary classification error and maintain a balance of 
optimal classification performance and the optimal 
number of radiomic features needed for binary 
classification (COVID-19 vs. non-COVID-19). 
 
As such, for the risk score using radiomic features only, 
only those 16 features with non-zero coefficients were 
selected via the LASSO process (Supplementary Table 
5 and Supplementary Figure 1). For the risk score 
combining radiomic features and clinical variables, only 
those five features with non-zero coefficients were 
selected via the LASSO process (two radiomic features, 
GLRLM_LRLGE_(25,90) and ID_Global_Max, plus 
three clinical variables, lesion number, LDH activity, 
and CK-MB activity) (Supplementary Table 6 and 
Supplementary Figure 2). 
 
After the feature dimensionality was reduced, a 
multivariable logistic regression analysis was employed 
and only the features with P < 0.001 in this process were 
selected to build the COVID-19 risk scores. For the risk 
score using radiomic features only, two radiomic 
features, GLRLM_LRLGE_(25,90) and ID_Global_ 
Max, were finally preserved (Supplementary Table 7). 
For the risk score combining radiomic features and 
clinical variables, seven features were further reduced to 
five features (two radiomic features, GLRLM_LRLGE_ 
(25,90) and ID_Global_Max, plus three clinical 
variables, lesion number, LDH activity, and CK-MB 
activity) (Supplementary Table 8). The COVID-19 risk 
scores using radiomic features only and using radiomics 
and clinical variables were built as the final classifiers by 
summing these features multiplied with their respective 
coefficients. 
 
The COVID-19 risk scores developed were also 
represented by nomograms. The threshold of using the 
risk score using radiomic features only to classify 
COVID-19 is 0.2. The threshold of using the risk score 
with combined radiomic and clinical variables to 
classify COVID-19 is 0.5. DCA was applied to evaluate 
the clinical decision utility of the COVID-19 risk scores 
developed [34, 35]. The definition of net benefit in the 
DCA is described in Supplementary Appendix 1. 
 
For the risk score using clinical factors only, the 
multivariable logistic regression analysis was directly 
employed and only the variables with P < 0.001 in this 
process were selected to build the COVID-19 risk score, 
including lesion number, LDH activity, and CK-MB 
activity (Supplementary Table 9). The COVID-19 risk 
score using clinical factors only was also represented by 
a nomogram. The threshold using a nomogram to 
classify COVID-19 is 0.5. 
 
Patient-based random forest models 
 
As a comparison to the patient-based COVID-19 risk 
scores developed, three random forest classifiers using 
radiomic features only, clinical factors only, and a 
combination of radiomic features and clinical factors 
were also constructed using grid search with fourfold 
cross-validation with the following parameters: the 
number of trees in the forest (ntree) = 500 and the 
maximum depth of the tree (mtry) = 3. 
 
Lesion-wise COVID-19 risk score with radiomic 
features only 
 
A lesion-based COVID-19 risk score using radiomic 
features alone was also built so that potentially different 
infectious lesions could be characterized individually. 
In total, 772 COVID-19 lesions were extracted from 
COVID-19 patients and 83 non-COVID-19 lesions were 
extracted from related viral pneumonia patients in this 
study. 
 
The feature dimensionality reduction was conducted to 
select the optimal radiomic features. Briefly, a total of 
1766 radiomic features were extracted from each lesion 
individually. After eliminating the radiomic features 
with null values and employing PCA, 32 radiomic 
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features were used for the Mann–Whitney U test 
(Supplementary Table 10). The Mann–Whitney U test 
further reduced the feature dimensions from 32 to 20 
features (Supplementary Table 11). The LASSO 
regression further selected the 10 non-redundant and 
most robust radiomic features (Supplementary Table 12 
and Supplementary Figure 3). 
 
After the feature dimensionality was reduced, the 
multivariable logistic regression analysis was employed 
to choose the radiomic features with P < 0.001 to build 
the lesion-based COVID-19 risk score with radiomic 
features alone so that 10 features were further reduced  
to 3 features: GLCM_Correlation_(25,0,1), ID_Local_ 
Range_Std, and GOH_Percentile_(15) (Supplementary 
Table 13). The lesion-based COVID-19 risk score based 
on three features only was also represented by a 
nomogram. The threshold of using the risk score to 
classify COVID-19 is 0.5. DCA was also employed to 
evaluate the clinical decision utility of the nomogram 
developed [43, 44]. 
 
Lesion-based weighted support vector machine 
analysis 
 
As a comparison to the lesion-based COVID-19 risk 
score using radiomic features alone, a lesion-based 
WSVM analysis was also conducted using the 10 
radiomic features (Supplementary Table 12) selected by 
the LASSO. The data distribution between the COVID-
19 and non-COVID-19 lesions (approximately 9.3:1) 
was extremely imbalanced. To ensure the models with 
predictive power were equally balanced between 
COVID-19 and non-COVID-19, a previously described 
strategy was used to adjust the distribution imbalance 
between COVID-19 and non-COVID-19 lesions and 
construct the WSVM [45]. 
 
Briefly, the strategy is to separate the major class (i.e., 
the COVID-19 lesion group in this study) into small 
subset groups size-comparable to the minor class (i.e., 
the non-COVID viral pneumonia lesion group in this 
study) to achieve a balanced distribution between the 
major class and the minor class; the COVID-19 lesion 
groups was randomly decomposed into nine partitions, 
and all the non-COVID-19 lesions were combined with 
each partition of COVID-19 lesions to form an 
individual subset so that the ratio of the COVID-19 and 
non-COVID-19 lesions was nearly 1:1 in each 
individual subset. In each individual subset, the total 
lesions were randomly separated into the training set 
(70%) and the validation set (30%). 
 
The support vector machine (SVM) was trained 
independently with 10 radiomic features selected by the 
LASSO process within the training set of each subset. 
The weight for the SVM was determined via the recall 
value of the prediction using the validation set to reduce 
the false negative rate. In each individual subset, the 
SVM generated was validated with the validation set of 
each subset (i.e., the balanced data of each subset) as 
well as the validation set of the entire data to evaluate 
the classification performances (Supplementary Table 14 
and Supplementary Figure 4). 
 
Finally, all constituent SVMs were combined by 
summing constituent SVMs multiplied by weights 
determined, divided by the sum of the weights. The 
classical (metric) multidimensional scaling matrix 
(CMDScale) was used to demonstrate the correlation of 
features and COVID-19 for each constituent SVM. 
 
Performance evaluation and statistical analysis 
 
The AUC between the risk scores and the random forest 
models and the WSVM model was compared using the 
Delong test. Six metrics, including precision, recall 
(sensitivity), specificity, F1, accuracy, and AUC, were 
calculated from the receiver operating characteristic 
(ROC) curve with the model output. 
 
The classification performances of COVID-19 by the 
developed risk scores were assessed by ROC analysis. 
For numeric variables, mean and standard deviation 
were calculated and the differences between COVID-19 
and non-COVID-19 patient groups were compared 
using rank-sum tests. A two-tailed P value less than 




The datasets analyzed in this study will be available 
from the corresponding author (Xiadong Li, email: 
lixiadong2019@outlook.com) at the time of publication. 
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limited access. Upon receiving access, the investigator 
may only use them for the purposes outlined in the 
request to the data provider, and redistribution of the 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Appendix 1 
 
Definition of net benefit in the decision curve 
analysis 
 
The net benefit [1, 2] was defined by the following 
equation: 
 











Pt is the “threshold possibility” to stratify the patients 
into high-risk COVID-19 or low-risk non-COIVD-19 
groups. Patients with a probability of having COVID-19 
higher than Pt are high-risk patients. TPR is the true 
positive rate, defined as the proportion of high-risk 
patients in the patients having COVID-19. FPR is the 
false positive rate, defined as the proportion of high-risk 
patients in the patients having non-COVID-19. ω is the 
prevalence of having COVID-19, calculated by dividing 
the total patients number by the number of patients with 
COVID-19. In this study, the treat-all scheme assumes 
that all the patients were COVID-19; the treat-none 
scheme assumes that all the patients were non-COVID-
19. In the condition of “treat none”, no patient is 
classified as high risk, both the TPR and FPR are zero, 
so the Net Benefit is zero. In the condition of “treat all”, 
all patients are classified as high risk COVID-19 
(TPR=FPR=1), so the Net Benefit is calculated as 
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Supplementary Appendix 2 
 
The procedure of using the nomogram of the risk 
score combining radiomic features and clinical 
factors 
 
This is the patient-based risk score integrating 2 
radiomic features and 3 clinical variables. For 
example, a suspicious patient was found having 
 the following radiomic features and clinical  
factors detected/calculated: lesions numbers = 5, 
GLRM_LRLGE_(25,90) = 0.3, ID_Global_Max = 
2000, lactate dehydrogenase =  750 u/mg, creatine 
kinase isoenzymes = 10 ug/L. The values in the Points 
line in the 1st row corresponding to these radiomic 
features and clinical factors are 28, 58, 17, 32, 48. As 
such, the total point adding all the values in the Points 
line is 183 in the Total points line in the 7th row. So, 
the patient's risk of COVID-19 can be calculated from 
this nomogram with a risk score close to 0.95. 
Alternatively, all radiomic features and clinical 
factors detected/calculated can be plugged into the 
risk score equation to get the score value: 
 
The patient based risk scorecombining radiomics
and clinical features












= − 14.053 9.529 5 122.045
0.3 0.0196 2000 0.334 750
7.593 10 183.9755
+  +




The score of 183.9755 is corresponding to 0.95 on the 
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Supplementary Appendix 3  
 
The influence of bias induced in the boundary and 
volume contoured in the manual delineating process 
on the radiomics values calculated 
 
To further verify the repeatability of two features 
GLRLM_LRLGE_ (25, 90) and ID_Global_Max 
selected in the construction of patient-based risk scores 
in this study, a verification study was conducted. A  
CT data set from one COVID-19 patient was used  
for delineation by five different radiologists and the 
differences of volumes and surface areas caused by 
different delineations were calculated (Supplementary 
Figure 6). The 5 volumes-of-interest (VOIs) delineated 
were also used for the GLRLM_LRLGE_ (25, 90) and 
ID_Global_Max feature extraction and calculation. 
Three different tools (2 open sources ((image biomarker 
explorer (IBEX) [3] and Pyradiomics [4]) and 1 in-
house Matlab codes) were used to extract and calculate 
the radiomic feature values of the GLRLM_LRLGE_ 
(25, 90) and ID_Global_Max. The patient-based 
COVID-19 risk score using radiomic features only was 
calculated using the radiomic features extracted from 5 
VOIs contoured according to the formula developed in 
this study (Equation 5). The results are shown in 
Supplementary Table 15 as follows. 
 
The patient-based risk scoreusing radiomic features only
3.785 19.563 GLRLM_LRLGE_(25,90) 0.002
ID_Global_Max




As shown in Supplementary Table 15, the VOI 
delineation biases induced by different radiologists had 
a relatively small impact on the radiomic feature values 
of GLRLM_LRLGE_ (25, 90) and ID_Global_Max as 
well as the COVID-19 risk score values calculated. In 
addition, the feature extractions on the VOIs contoured 
using different tools had not significantly affected the 
calculation of COVID-19 risk score, which could be 
considered to be a good repeatability. 
 
Furthermore, the same verification study was also 
repeated on three radiomic features identified in the 
lesion based analysis and the results were shown in 
Supplementary Table 16. Similarly, the VOI delineation 
biases induced by different radiologists had a relatively 
small impact on the radiomic feature values of 
GOH_Percentile_(15), GLCM_Correlation_(25,0,1) and 
ID_Local_range_std as well as the COVID-19 risk score 
values calculated. In addition, the feature extractions on 
the VOIs contoured using different tools had not 
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Supplementary Figure 1. The LASSO process to select the radiomic features for the construction of the patient-based risk 
score using radiomic features only. (A) The radiomic features selection procedure using LASSO regression method. To determine the 
best features combination for building the risk score, the control parameter λ value in the LASSO model was selected via 4-fold cross-
validation with minimum criteria. The x-axis is the value of log (λ) and the y-axis is the binominal deviance in the 4-fold cross validation 
method 100 times. The upper x-axis is the number of non-zero-coefficient features with a given λ. The red curve indicated the average 
binominal deviance value with the vertical bars showing the upper and lower boundaries. The left vertical dotted line defined the λ with the 
least binomial deviance. The right vertical dotted line indicates the largest value of λ such that the binominal deviance is within one standard 
error of the minimum binominal deviance. (B) The LASSO coefficient profiles of the radiomic features. The figure shows the feature 
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Supplementary Figure 2. The LASSO process to select the radiomics features and clinical variables for the construction of the 
patient-based risk score combining radiomic features and clinical variables. (A) The radiomic features and clinical variables 
selection procedure using LASSO regression method. To determine the best features combination for building the risk score, the control 
parameter λ value in the LASSO model was selected via 4-fold cross-validation with minimum criteria. The x-axis is the value of log (λ) and the 
y-axis is the binominal deviance in the 4-fold cross validation method 100 times. The upper x-axis is the number of non-zero-coefficient 
features with a given λ. The red curve indicated the average binominal deviance value with the vertical bars showing the upper and lower 
boundaries. The left vertical dotted line defined the λ with the least binomial deviance. The right vertical dotted line indicates the largest 
value of λ such that the binominal deviance is within one standard error of the minimum binominal deviance. (B) The LASSO coefficient 
profiles of the 17 radiomic features and clinical variables. The figure shows the feature coefficient change with the tuning of λ value. The 
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Supplementary Figure 3. The LASSO process to select the radiomic features for the construction of lesion-based risk score 
using radiomic features alone. (A) The radiomic features selection procedure using LASSO regression method. To determine the best 
features combination for building the risk score, the control parameter λ value in the LASSO model was selected via 4-fold cross-validation 
with minimum criteria. The x-axis is the value of log (λ) and the y-axis is the binominal deviance in the 4-fold cross validation method 100 
times. The upper x-axis is the number of non-zero-coefficient features with a given λ. The red curve indicated the average binominal deviance 
value with the vertical bars showing the upper and lower boundaries. The left vertical dotted line defined the λ with the least binomial 
deviance. The right vertical dotted line indicates the largest value of λ such that the binominal deviance is within one standard error of the 
minimum binominal deviance. (B) The LASSO coefficient profiles of the radiomic features. The figure shows the feature coefficient change 
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Supplementary Figure 4. The correlation of radiomics features and COVID-19 for each constituent SVM. (A, C, E, G, I, K, M, O, 
Q): The heat maps of correlation of radiomics features and COVID-19 for 9 individual constituent SVM. (B, D, F, H, J, L, N, P, R): The classical 
(metric) multidimensional scaling matrix to demonstrate the discriminative abilities of the individual constituent SVM to classify COVID-19 




Supplementary Figure 5. The geographic distribution of 130 radiologists from 10 provinces in China including Hubei 
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Supplementary Tables 
 
Please browse Full Text version to see the data of Supplementary Tables 15, 16. 
 
Supplementary Table 1. The 32 radiomic features selected by principal component analysis (PCA) for dimensionality 
reduction to construct the patient-based risk score using radiomic features only. 
Radiomic features Coefficients Cumulative% Explainable variance ratio% 
Shape_Convex 0.913  37.116 37.116 
Shape_Convex_Hull_Volume 0.926  54.347 17.231 
GOH_Percentile_(15) 0.933  66.221 11.874 
GOH_Percentile_(50) 0.979  75.455 9.234 
GLCM_Cluster_Prominence_(25,333,4) 0.901  80.369 4.914 
GLCM_Cluster_Prominence_(25,315,4) 0.972  84.221 3.852 
GLCM_Cluster_Shade_(25,333,4) 0.754  86.194 1.973 
GLCM_Cluster_Shade_(25,315,4) 0.829  87.825 1.631 
GLCM_Cluster_Shade_(25,315,7) 0.936  89.214 1.389 
GLCM_Contrast_(25,0,10) 0.689  90.605 1.391 
GLCM_Contrast_(25,90,7) 0.757  91.711 1.106 
GLCM_Contrast_(25,270,4) 0.837  92.582 0.871 
GLCM_Correlation_(25,0,1) 0.306  93.401 0.819 
GLCM_Correlation_(25,0,4) 0.954  94.124 0.723 
GLCM_Correlation_(25,90,4) 0.661  94.813 0.689 
GLCM_Difference_Entropy_(25,333,1) 0.396 95.446 0.633 
GLCM_Dissimilarity_(25,333,7) 0.925  95.967 0.521 
GLCM_Energy_(25,45,4) 0.931  96.548 0.581 
GLCM_Energy_(25,45,7) 0.486  96.985 0.437 
GLCM_Energy_(25,135,4) 0.654  97.386 0.401 
GLCM_Information_Measure_Corr1_(25,0,1) 0.671  97.782 0.396 
GLCM_Information_Measure_Corr2_(25,315,1) 0.432  98.097 0.315 
GLCM_Inverse_Diff_Moment_Norm_(25,135,4) 0.779  98.395 0.298 
GLCM_Inverse_Diff_Moment_Norm_(25,225,4) 0.828  98.672 0.277 
GLCM_Inverse_Diff_Moment_Norm_(25,270,7) 0.669  98.884 0.212 
GLCM_Inverse_Variance_(25,225,4) 0.534 99.093 0.209 
GLCM_Inverse_Variance_(25,315,4) 0.289  99.287 0.194 
GLCM_Max_Probability_(25,180,1) 0.275  99.454 0.167 
GLCM_Sum_Entropy_(25,180,7) 0.439  99.602 0.148 
ID_Kurtosis 0.354  99.74 0.138 
ID_Local_Range_Std 0.119  99.879 0.139 
IH_Percentile_Area_(30) 0.387  100 0.121 
The values in the brackets represent the parameters used to calculate that particular radiomic feature. 
  
 
www.aging-us.com 9217 AGING 
Supplementary Table 2. The 20 radiomic features plus 6 clinical variables selected by principal component analysis 
(PCA) for dimensionality reduction to construct the patient-based risk score combining radiomic features and clinical 
variables. 
Radiomic features and clinical variables Coefficients Cumulative% Explainable variance ratio% 
Lesion number 0.866 33.623 33.623 
Lactate dehydrogenase 0.829 44.588 10.965 
C-reactive protein 0.756 53.795 9.207 
Gender 0.932 61.926 8.131 
White blood cell 0.689 69.029 7.103 
D-dimers 0.832 75.902 6.873 
Shape_Compactness_(2) 0.911 81.423 5.521 
Shape_Convex_Hull_Volume 0.874 85.786 4.363 
Shape_Orientation 0.829 88.938 3.152 
Shape_Roundness 0.543 91.042 2.104 
GOH_Percentile_Area_(15) 0.886 92.476 1.434 
GOH_Percentile_Area_(70) 0.851 93.494 1.018 
GOH_Range 0.944 94.497 1.003 
GLCM_Cluster_Prominence_(25,333,4) 0.756 95.499 1.002 
GLCM_Cluster_Shade_(25,333,4) 0.813 96.400 0.901 
GLCM_Correlation_(25,333,1) 0.925 97.143 0.743 
GLCM_Correlation_(25180,7) 0.866 97.620 0.477 
GLCM_Difference_Entropy_(25,333,1) 0.862 98.081 0.461 
GLCM_Information_Measure_Corr_(2,25,333,7) 0.642 98.533 0.452 
GLCM_Max_Probability_(25,333,1) 0.473 98.845 0.312 
GLCM_Max_Probability_(250,7) 0.455 99.078 0.233 
GLRLM_Long_Run_Low_Gray_Level_Empha_(2590) 0.856 99.289 0.211 
ID_Global_Max 0.865 99.498 0.209 
ID_Local_Entropy_Std 0.674 99.699 0.201 
ID_Percentile_(30) 0.498 99.863 0.164 
IH_Percentile_(30) 0.563 100.000 0.137 
The values in the brackets represent the parameters used to calculate that particular radiomic feature. 
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Supplementary Table 3. The 20 radiomic features selected by the Mann-Whitney U test for dimensionality reduction 
to construct the patient-based risk score using radiomic features only. 
Radiomic feature AUC 95% CI P 
Shape_Convex_Hull_Volume 0.704 0.664-0.808 0.000 
GOH_Percentile_(15) 0.890 0.828-0.921 0.000 
GOH_Percentile_(50) 0.688 0.618-0.778 0.321 
GLCM_Cluster_Prominence_(25,333,4) 0.544 0.464-0.632 0.467 
GLCM_Cluster_Prominence_(25,315,4) 0.509 0.458-0.613 0.218 
GLCM_Cluster_Shade_(25,315,7) 0.438 0.367-0.557 0.000 
GLCM_Correlation_(25,0,1) 0.853 0.803-0.903 0.000 
GLCM_Contrast_(25,0,1) 0.972 0.912-0.998 0.000 
GLCM_Contrast_(25,270,4) 0.781 0.713-0.872 0.000 
GLCM_Difference_Entropy_(25,333,1) 0.940 0.876-0.984 0.000 
GLCM_Dissimilarity_(25,333,7) 0.532 0.429-0.613 0.311 
GLCM_Energy_(25,135,4) 0.557 0.465-0.604 0.231 
GLCM_Energy_(25,225,4) 0.532 0.487-0.612 0.367 
GLCM_Information_Measure_Corr1_(25,0,1) 0.623 0.539-0.719 0.000 
GLCM_ Information_Measure_Corr2_(25,315,1) 0.567 0.509-0.633 0.000 
GLCM_Inverse_Diff_Moment_Norm_(25,90,7) 0.540 0.512-0.634 0.000 
GLCM_Inverse_Diff_Moment_Norm_(25,270,7) 0.677 0.621-0.759 0.000 
GLCM_Sum_Entropy_(25,180,7) 0.684 0.589-0.704 0.000 
ID_Kurtosis 0.734 0.633-0.811 0.000 
ID_Local_Range_Std 0.976 0.909-0.994 0.216 
The values in the brackets represent the parameters used to calculate that particular radiomic feature. 
 
Supplementary Table 4. The 11 radiomic features and 6 clinical variables selected by the Mann-Whitney U test for 
dimensionality reduction to construct COVID-19 risk score using radiomic features and clinical variables. 
Radiomic features and clinical variables AUC 95% CI P Value 
Lesion number 0.956 0.909-0.994 0.000 
Gender 0.463 0.274-0.554 0.673 
White blood cell 0.394 0.369-0.551 0.421 
C-reactive protein 0.674 0.593-0.751 0.000 
Lactate dehydrogenase 0.887 0.804-0.915 0.000 
Creatine kinase isoenzyme 0.069 0.036-0.081 0.000 
Shape_Compactness_(2) 0.365 0.278-0.434 0.003 
GOH_Range 0.678 0.576-0.717 0.000 
GLCM_Cluster_Prominence_(25,333,4) 0.604 0.512-0.723 0.004 
GLCM_Correlation_(25,333,1) 0.287 0.209-0.353 0.000 
GLCM_Difference_Entropy_(25,333,1) 0.724 0.667-0.771 0.000 
GLCM_MaxProbability_(250,7) 0.365 0.312-0.423 0.009 
GLRLM_LRLGE_(25,90) 0.767 0.676-0.812 0.000 
ID_GlobalMax 0.791 0.695-0.853 0.000 
ID_Percentile_(30) 0.368 0.311-0.467 0.001 
IH_Percentile_(30) 0.303 0.286-0.431 0.003 
IH_Percentile_Area 0.387 0.271-0.463 0.000 
The values in the brackets represent the parameters used to calculate that particular radiomic feature. 
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Supplementary Table 5. The 16 radiomic feature selected by the LASSO for 
dimensionality reduction to construct the patient-based risk score using 
radiomic features only. 


















The values in the brackets represent the parameters used to calculate that particular 
radiomic feature. 
 
Supplementary Table 6. The 2 radiomic features and 3 clinical 
variables selected by the LASSO for dimensionality reduction to 
construct COVID-19 risk score using radiomic features and clinical 
variables. 
Radiomic features and clinical variables Lambda 
Intercept -1.088064e+00 
Lesion number 3.450725e-01 
Lactate dehydrogenase 4.697555e-01 
Creatine kinase isoenzyme 3.636614e-05 
GLRLM_LRLGE_(25,90) 5.842366e-03 
ID_GlobalMax -1.605967e-01 
The values in the brackets represent the parameters used to calculate that 
particular radiomic feature. 
 
Supplementary Table 7. The 2 radiomic features selected by the multivariable logistic regression to construct the 
patient-based risk score using radiomic features only in the training set. 
 Coef S.E. Wald Z Pr(>|Z|) AUC 95% CI  
Intercept -3.785  27.834 -4.25 0.898 .. .. 
GLRLM_LRLGE_(25, 90) 19.563  175.031 7.27 <0.0001 0.813 0.698-0.876 
ID_Global_Max 0.002  0.017 0.14 0.002 0.853 0.668-0.814 
The values in the brackets represent the parameters used to calculate that particular radiomic feature. 
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Supplementary Table 8. The 2 radiomic features and 3 clinical variables used by the multivariable logistic regression 
to construct the COVID-19 risk score using radiomic features and clinical variables in training set. 
 Coef S.E. Wald Z Pr(>|Z|) AUC 95% CI 
Intercept -114.053 559.175 -0.11 0.765 .. .. 
Lesion number 9.311 31.132 9.59 <0.0001 0.823 0.793-0.906 
GLRLM_LRLGE_(25, 90) 122.045 687.176 2.14 <0.0001 0.718 0.624-0.845 
ID_Global_Max 0.0196 0.045 3.08 0.001 0.786 0.667-0.822 
Lactate dehydrogenase 0.334 2.063 7.21 <0.0001 0.861 0.779-0.916 
creatine kinase isoenzymes -7.593 38.179 -6.23 <0.0001 0.856 0.793-0.991 
The values in the brackets represent the parameters used to calculate that particular radiomic feature. 
 
Supplementary Table 9. The 3 clinical variables used by the multivariable logistic regression to construct the patient-
based risk score using clinical variables only in the training set. 
 Coef S.E. Wald Z Pr(>|Z|) AUC 95% CI  
Intercept -15.680  134.812 -8.13 0.898 .. .. 
Lesion number 2.833  17.532 2.31 <0.0001 0.812 0.749-0.917 
Lactate dehydrogenase 0.104  1.337 1.19 <0.0001 0.857 0.813-0.906 
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Supplementary Table 10. The 32 radiomics features selected by principal component analysis (PCA) for 
dimensionality reduction to construct lesion-based risk score using radiomic features only. 
Radiomic Features Coefficients Cumulative% Explainable variance ratio% 
Shape_Convex 0.919  36.680  36.680  
Shape_Convex_Hull_Volume 0.977  19.417  56.098  
GOH_Percentile_(15) 0.867  10.496  66.593  
GOH_Percentile_(50) 0.867  9.244  75.837  
GLCM_Cluster_Prominence_(25,333,4) 0.912  4.470  80.307  
GLCM_Cluster_Prominence_(25,315,4) 0.858  2.653  82.961  
GLCM_Cluster_Shade_(25,333,4) 0.673  1.839  84.800  
GLCM_Cluster_Shade_(25,315,4) 0.895  1.568  86.368  
GLCM_Cluster_Shade_(25,315,7) 0.920  1.319  87.687  
GLCM_Contrast_(25,0,10) 0.494  1.255  88.942  
GLCM_Contrast_(25,90,7) 0.695  1.161  90.103  
GLCM_Contrast_(25,270,4) 0.817  1.012  91.116  
GLCM_Correlation_(25,0,1) 0.208  0.922  92.038  
GLCM_Correlation_(25,0,4) 0.850  0.844  92.882  
GLCM_Correlation_(25,90,4) 0.659  0.785  93.667  
GLCM_Difference_Entropy_(25,333,1) 0.569  0.734  94.401  
GLCM_Dissimilarity_(25,333,7) 0.819  0.686  95.087  
GLCM_Energy_(25,45,4) 0.878  0.658  95.745  
GLCM_Energy_(25,45,7) 0.401  0.647  96.392  
GLCM_Energy_(25,135,4) 0.418  0.634  97.026  
GLCM_Information_Measure_Corr1_(25,0,1) 0.618  0.595  97.621  
GLCM_Information_Measure_Corr2_(25,315,1) 0.412  0.536  98.157  
GLCM_Inverse_Diff_Moment_Norm_(25,135,4) 0.468  0.515  98.673  
GLCM_Inverse_Diff_Moment_Norm_(25,225,4) 0.781  0.383  99.056  
GLCM_Inverse_Diff_Moment_Norm_(25,270,7) 0.676  0.132  99.189  
GLCM_Inverse_Variance_(25,225,4) 0.476  0.107  99.295  
GLCM_Inverse_Variance_(25,315,4) 0.178  0.093  99.388  
GLCM_Max_Probability_(25,180,1) 0.211  0.086  99.474  
GLCM_Sum_Entropy_(25,180,7) 0.365  0.081  99.555  
ID_Kurtosis 0.313  0.064  99.620  
ID_Local_Range_Std 0.121  0.045  99.665  
IH_Percentile_Area_(30) 0.371  0.043  99.708  
The values in the brackets represent the parameters used to calculate that particular radiomic feature. 
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Supplementary Table 11. The 20 radiomics features selected by the Mann-Whitney U test for dimensionality 
reduction to construct the lesion-based risk score using radiomic features only. 
Radiomic feature AUC 95% CI P 
Shape_Convex_Hull_Volume 0.715 0.618-0.757 0.000 
GOH_Percentile_(15) 0.837 0.768-0.954 0.000 
GOH_Percentile_(50) 0.669 0.607-0.779 0.172 
GLCM_Cluster_Prominence_(25,333,4) 0.499 0.401-0.681 0.305 
GLCM_Cluster_Prominence_(25,315,4) 0.480 0.396-0.557 0.172 
GLCM_Cluster_Shade_(25,315,7) 0.441 0.348-0.567 0.000 
GLCM_Correlation_(25,0,1) 0.809 0.731-0.898 0.001 
GLCM_Contrast_(25,0,1) 0.884 0.715-0.918 0.000 
GLCM_Contrast_(25,270,4) 0.713 0.647-0.862 0.003 
GLCM_Difference_Entropy_(25,333,1) 0.837 0.778-0.925 0.000 
GLCM_Dissimilarity_(25,333,7) 0.493 0.418-0.553 0.551 
GLCM_Energy_(25,135,4) 0.511 0.449-0.654 0.106 
GLCM_Energy_(25,225,4) 0.474 0.388-0.591 0.493 
GLCM_Information_Measure_Corr1_(25,0,1) 0.570 0.469-0.670 0.001 
GLCM_ Information_Measure_Corr2_(25,315,1) 0.529 0.844-0.635 0.000 
GLCM_Inverse_Diff_Moment_Norm_(25,90,7) 0.542 0.684-0.627 0.000 
GLCM_Inverse_Diff_Moment_Norm_(25,270,7) 0.712 0.667-0.749 0.001 
GLCM_Sum_Entropy_(25,180,7) 0.732 0.675-0.138 0.000 
ID_Kurtosis 0.714 0.677-0.845 0.000 
ID_Local_Range_Std 0.932 0.889-0.989 0.305 
The values in the brackets represent the parameters used to calculate that particular radiomic feature. 
 
Supplementary Table 12. The 10 radiomic features selected by the LASSO for 
dimensionality reduction to construct the lesion-based risk score using radiomic 
features only. 
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Supplementary Table 13. The 3 radiomic features used by the multivariable logistic regression to construct the 
lesion-based risk score using radiomic features only. 
  Coefficient Standard error Wald Z Pr(>|Z|) AUC 95% CI 
Intercept -55.389  62.895  -0.976  0.413  - - 
GLCM_Correlation_(25, 0, 1) -6.769  5.811  -5.023  <0.0001 0.718  0.665-0.874 
ID_Local_Range_Std 0.033  0.002  3112  <0.0001 0.753  0.633-0.819 
GOH_Percentile_(15) 0.136  0.052  4.153  0.002  0.798  0.771-0.804 
 
Supplementary Table 14. The diagnostic performance of individual 9 constituent SVMs. 
9 Individual constituent SVM Validation dataset Precision Recall F1 AUC 95% CI    P value 
SUB-SVM1 G1 1.000  0.846  0.917  0.909 0.895-0.923 
SUB-SVM2 G2 0.952  1.000  0.976  0.963 0.934-0.978 
SUB-SVM3 G3 1.000  0.833  0.909  0.9 0.892-0.912 
SUB-SVM4 G4 1.000  0.871  0.931  0.889 0.878-0.892 
SUB-SVM5 G5 1.000  0.839  0.912  0.96 0.943-0.965 
SUB-SVM6 G6 1.000  0.867  0.929  0.937 0.923-0.945 
SUB-SVM7 G7 1.000  0.893  0.943  0.944 0.954-0.962 
SUB-SVM8 G8 1.000  0.906  0.951  0.933 0.925-0.943 
SUB-SVM9 G9 1.000  0.879  0.935  0.929 0.904-0.937 
SUB-SVM-average AVERAGE 0.995  0.882  0.934  0.929  0.912-0.934   0.231 
SVM TOTAL 0.962  0.979  0.970  0.882 0.823-0.915 
Model-G1 TOTAL 1.000  0.862  0.926  0.920  0.907-0.933 
Model-G2 TOTAL 1.000  0.877  0.935  0.930  0.918-0.943 
Model-G3 TOTAL 1.000  0.867  0.929  0.924  0.913-0.938 
Model-G4 TOTAL 1.000  0.868  0.930  0.924  0.912-0.937 
Model-G5 TOTAL 1.000  0.872  0.932  0.927  0.914-0.939 
Model-G6 TOTAL 1.000  0.873  0.932  0.928  0.915-0.940 
Model-G7 TOTAL 1.000  0.873  0.932  0.928  0.915-0.940 
Model-G8 TOTAL 1.000  0.869  0.930  0.925  0.912-0.938 
Model-G9 TOTAL 1.000  0.875  0.933  0.923  0.906-0.940 
Model-G-average AVERAGE 1.000  0.871  0.931  0.925  0.912-0.939   0.226 
WSVM TOTAL 0.999  0.884  0.968  0.958  0.943-0.967   0.000 
The COVID-19 lesion groups was randomly decomposed into 9 partitions, and all the non-COVID-19 lesions were combined 
with each partition of COVID-19 lesions to form an individual subset (i.e., group1 (G1) –group9 (G9)). 
P values: P = 0.231 represents that there are no significant differences between SUB-SVMi (i=1-9); P = 0.226 represents that 
there are no significant differences between Model-Gi (i=1-9); P = 0.000 represents that there are significant differences 
between SUB-SVM-average, Model-G-average and WSVM. 
Abbreviations: WSVM, weighted support vector machine. 
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Supplementary Table 15. The comparison of the variation of contours by different radiologists and its impact on the 
calculation of COVID-19 risk score using radiomic feature only (patient based analysis). 
 
Supplementary Table 16. The comparison of the variation of contours by different radiologists and its impact on the 
calculation of COVID-19 risk score using radiomic feature only (lesion based analysis). 
 
